




































































Cancers 2021, 13, 3296. https://doi.org/10.3390/cancers13133296 www.mdpi.com/journal/cancers 
Review 
Myelodysplastic Syndromes in the Postgenomic Era and Future 
Perspectives for Precision Medicine 
Ioannis Chanias 1,†, Kristina Stojkov 1,2,†, Gregor Th. Stehle 3, Michael Daskalakis 1,2, Helena Simeunovic 1,  
Linet Muthoni Njue 1, Annatina S. Schnegg-Kaufmann 1,2, Naomi A. Porret 1, Ramanjaneyulu Allam 1,2,  
Tata Nageswara Rao 1,2, Rudolf Benz 4, Axel Ruefer 5, Adrian Schmidt 6, Marcel Adler 7, Alicia Rovo 1,  
Stefan Balabanov 8, Georg Stuessi 9, Ulrike Bacher 1, Nicolas Bonadies 1,2,*  
and on behalf of the Swiss MDS Study Group ‡ 
1 Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, 
University of Bern, 3010 Bern, Switzerland; ioannis.chanias@insel.ch (I.C.); kristina.stojkov@insel.ch (K.S.); 
michael.daskalakis@insel.ch (M.D.); helena.simeunovic@insel.ch (H.S.);  
LinetMuthoni.Njue@insel.ch (L.M.N.); Annatina.Schnegg@insel.ch (A.S.S.-K.);  
NaomiAzur.Porret@insel.ch (N.A.P.); allam.ramanjaneyulu@dbmr.unibe.ch (R.A.);  
tata.nageswararao@dbmr.unibe.ch (T.N.R.); Alicia.Rovo@insel.ch (A.R.); veraulrike.bacher@insel.ch (U.B.) 
2 Department for BioMedical Research (DBMR), University of Bern, 3010 Bern, Switzerland 
3 Clinic of Hematology, University Hospital Basel, 4031 Basel, Switzerland; GregorThomas.Stehle@usb.ch 
4 Department of Hematology and Oncology, Hospital Thurgau AG, 8596 Muensterlingen, Switzerland;  
rudolf.benz@stgag.ch 
5 Department of Hematology and Central Hematology Laboratory, Cantonal Hospital Lucerne, 6004 Lucerne, 
Switzerland; axel.ruefer@luks.ch 
6 Department of Internal Medicine, Clinic of Medical Oncology and Hematology, City Hospital Waid and 
Triemli, 8063 Zurich, Switzerland; Adrian.Schmidt@triemli.zuerich.ch 
7 Center for Medical Oncology and Hematology, Hospital Thun, 3600 Thun, Switzerland;  
marcel.adler@spitalstsag.ch 
8 Department of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich,  
8091 Zurich, Switzerland; stefan.balabanov@usz.ch 
9 Clinic of Hematology, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland; 
Georg.Stuessi@eoc.ch 
* Correspondence: Nicolas.Bonadies@insel.ch; Tel.: +41-(0)31-632-4571; Fax:+41-(0)31-632-3406 
† Shared first authorship. 
‡ Membership of the Swiss MDS Study Group is provided in the Acknowledgments.  
Simple Summary: With demographic ageing, improved cancer survivorship and increased diag-
nostic sensitivity, incident cases of patients with Myelodysplastic Syndromes (MDS) are continu-
ously rising, leading to a relevant impact on health care resources. Disease heterogeneity and vari-
ous comorbidities are challenges for the management of the generally elderly patients. Therefore, 
experienced physicians and multidisciplinary teams should be involved in the establishment of the 
correct diagnosis, risk-assessment and personalized treatment plan. Next-generation sequencing 
allows for early detection of clonal hematopoiesis and monitoring of clonal evolution, but also poses 
new challenges for its appropriate use. At present, allogeneic hematopoietic stem cell transplanta-
tion remains the only curative treatment option for a minority of fit MDS patients. All others receive 
palliative treatment and will eventually progress, having an unmet need for novel therapies. Tar-
geting compounds are in prospect for precision medicine, however, abrogation of clonal evolution 
to acute myeloid leukemia remains actually out of reach. 
Abstract: Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal disorders 
caused by sequential accumulation of somatic driver mutations in hematopoietic stem and progen-
itor cells (HSPCs). MDS is characterized by ineffective hematopoiesis with cytopenia, dysplasia, 
inflammation, and a variable risk of transformation into secondary acute myeloid leukemia. The 
advent of next-generation sequencing has revolutionized our understanding of the genetic basis of 
the disease. Nevertheless, the biology of clonal evolution remains poorly understood, and the sto-
chastic genetic drift with sequential accumulation of genetic hits in HSPCs is individual, highly 
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dynamic and hardly predictable. These continuously moving genetic targets pose substantial chal-
lenges for the implementation of precision medicine, which aims to maximize efficacy with minimal 
toxicity of treatments. In the current postgenomic era, allogeneic hematopoietic stem cell transplan-
tation remains the only curative option for younger and fit MDS patients. For all unfit patients, 
regeneration of HSPCs stays out of reach and all available therapies remain palliative, which will 
eventually lead to refractoriness and progression. In this review, we summarize the recent advances 
in our understanding of MDS pathophysiology and its impact on diagnosis, risk-assessment and 
disease monitoring. Moreover, we present ongoing clinical trials with targeting compounds and 
highlight future perspectives for precision medicine. 




MDS is a heterogeneous group of clonal conditions arising from somatic mutations 
in hematopoietic stem and progenitor cells (HSPCs), mainly affecting elderly individuals 
[1]. Ineffective hematopoiesis in MDS is characterized by a vicious circle of maturation 
defects (dysplasia), inflammation in the bone marrow (BM) microenvironment and cyto-
penia in peripheral blood (PB), which is accompanied by variable risk of progressing to-
wards secondary Acute Myeloid Leukemia (sAML) [2]. The median age at presentation is 
above 70 years, with an age-standardized incidence-rate of 3–5 cases per 100,000 patient-
years and a prevalence of 20 patients per 100,000 individuals [3]. The age-specific inci-
dence-rate increases progressively with age, with >50 cases per 100,000 patient-years in 
individuals >75 years [3,4]. Males are predominantly affected, with the exception of MDS 
with isolated del(5q), which is more frequent in females. Therapy-related MDS is esti-
mated to represent 10% of all MDS cases, though precise incidence rates cannot be deter-
mined from current epidemiological data [5,6]. Although generally a disease of the el-
derly, MDS can occur at any age. The presence of genetic predisposition syndromes 
should be thoroughly investigated in childhood or younger adults (<40 years). In such 
cases, multiple organs can be affected, and these individuals carry a risk for increased 
toxicity to chemotherapy and development of other cancers [7,8]. 
2. Pathophysiology 
2.1. Recurrent Somatic Leukemia-Associated Driver Mutations and Clonal Hematopoiesis 
Next-generation sequencing (NGS) has revolutionized our understanding of the ge-
netic landscape in MDS. Nonetheless, the precise molecular mechanisms involved in 
clonal dominance and evolution remain unclear [9]. NGS allowed the identification of re-
current somatic leukemia-associated driver mutations (SLADMs) in genes that are classi-
fied into RNA-splicing factors, epigenetic regulators, transcription factors, cell-cycle reg-
ulators, cohesin complex factors, as well as cell-signaling molecules (Table 1) [10–15]. Evo-
lution from clonal hematopoiesis to MDS and sAML is caused by sequential accumulation 
of random genetic hits in HSPCs with many mechanisms involved. Genetic drift origi-
nates from cell-intrinsic growth advantage, reduced cell-death and selective pressure im-
posed by a variety of cell-extrinsic factors. These can include radiation, chemotherapy, 
cytotoxic drugs and many other toxins (i.e., benzol exposition) [16]. Further genetic drift 
can be promoted by coexisting intrinsic DNA repair defects, loss of immunogenic tumor 
surveillance, remodeling of the BM microenvironment and other niche-factors associated 
with ageing [17] (Figure 1). Age-related clonal hematopoiesis (ARCH) and clonal hema-
topoiesis of indeterminate potential (CHIP) are defined by the presence of SLADMs at a 
variant allele frequency (VAF) ≥2% in individuals without cytopenia or other signs of he-
matologic disease. CHIP is a relevant phenomenon observed in the ageing population, 
Cancers 2021, 13, 3296 3 of 35 
 
 
affecting 20–40% of individuals >80 years, and associated with an increased risk for trans-
formation to overt hematological malignancies [18–22] (Table 2). The term Clonal Cytopenia 
of Unknown Significance (CCUS) refers to individuals with cytopenia and clonal hemato-
poiesis that do not fulfill the formal diagnostic criteria for MDS [19]. As clonal hematopoi-
esis is a frequent condition, the borderlines between facultative clonal pre-cancerous con-
ditions, non-neoplastic aplastic anemia and overt myeloid malignancies are increasingly 
blurred. The types of genes affected by somatic mutations, numbers of mutations and size 
of the mutated clone estimated by the VAF may help to distinguish these entities (Table 
3). 
 
Figure 1. Factors involved in clonal evolution (adapted from [16]). CHIP: clonal hematopoiesis of indeterminate potential; 
MDS: myelodysplastic syndromes; sAML: secondary AML; CTX: chemotherapy; RT: radiotherapy. 
Table 1. Recurrently mutated leukemia associated driver genes in MDS [11]. 
Class Gene Approx. Frequency (%) 
RNA-splicing factors SF3B1 * 25–30 
 SRSF2 10–15 
 U2AF1 5–10 
 ZRSR2 5 
 SF3A1 1–2 
 SF1 1–2 
 U2AF65 1–2 
 PRPF40B 1–2 
Epigenetic regulators TET2 20–25 
 DNMT3A 15 
 ASXL1 10–15 
 EZH2 5 
 IDH1 1–2 
 IDH2 1–2 
Transcription factors RUNX1 ♯ 10–20 
 SETBP1 1–2 
 ETV6 ♯ 2 
 CEBPA ♯ 1–2 
 GATA2 ♯ 1–2 
Cell-cycle regulators TP53 5–10 
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 PTEN 1 
Cohesin complex factors STAG1 1 
 STAG2 6 
 RAD21 1 
Cell-signaling molecules NRAS/KRAS 5–10 
 NPM1 1–2 
 JAK2 1–2 
 FLT3 2 
 CBL 1–2 
Selection of the most frequent genes affected by recurrent leukemia-associated driver mutations in 
MDS. Frequencies are only indicative, since they were extracted from studies also including mye-
loid neoplasms other than MDS. * High association with ring sideroblasts. ♯ Somatic as well as con-
stitutional gene mutations. 
Table 2. Definition of CHIP. 
- Absence of relevant cytopenia in the PB  
- Evidence of clonality: SLADMs with a VAF of ≥2% 
- No evidence of morphologic criteria for any hematologic neoplasm  
- PNH, MGUS, and MBL excluded 
If relevant cytopenia in PB is present, consider CCUS (minimal diagnostic criteria for MDS are not 
fulfilled) or MDS (minimal diagnostic criteria are fulfilled).  
Annual risk of progression to hematologic neoplasm: 0.5–1% 
CHIP, clonal hematopoiesis of indeterminate potential; CCUS, clonal cytopenia of undetermined 
significance; ICUS, idiopathic cytopenia of indeterminate significance; MBL, monoclonal B-lym-
phocytosis; MDS, myelodysplastic syndrome; MGUS, monoclonal gammopathy of undetermined 
significance; PB: peripheral blood; PNH, paroxysmal nocturnal hemoglobinuria; SLADMs: so-
matic leukemia-associated driver mutations; VAF: variant allele frequency. Minimal diagnostic 
criteria are according to MDS International Working Group (MDS-IWG) [23]. 
Table 3. Landscape of clonal hematopoiesis. 
 CHIP [20–22] AA [24,25]  CCUS MDS [10,11] 
Frequency  
~2% (40–49 years) 
~3% (50–59 years) 
~6% (60–69 years) 
~10% (70–79 years) 
~15% (80–89 years)  
19–47% 
(median age 44 
years) 
35% of ICUS  
70–80%  





ASXL1, JAK2  




DNMT3A, ASXL1  
TET2, DNMT3A, 










chemic stroke,  
diabetes mellitus 
type 2  
Good prognosis:  
PIGA, 
BCOR/BCORL1  
Poor prognosis:  
ASXL1, 
DNMT3A 
Increased risk for 
MDS/AML  
Good prognosis:  
SF3B1 






Mean VAF (%)  9%  
20%  
(<10% in 40% of 
patients) 
30%  30%  
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 CHIP [20–22] AA [24,25]  CCUS MDS [10,11] 
Mean number 
of mutations 
per patient  
1  
(93% of individuals)  
1 (64–90% of  
patients) 
1  3 (range 0–12)  
AA: Aplastic anemia; CHIP: clonal hematopoiesis of indeterminate potential; CCUS: clonal cyto-
penia of undetermined significance; ICUS: idiopathic cytopenia of undetermined significance; 
SLADMs: somatic leukemia-associated driver mutations; VAF: variant allele frequency. 
2.2. The Role of Adaptive and Innate Immunity in MDS 
Clonal hematopoiesis is associated with increased cardiovascular morbidity, includ-
ing premature atherosclerosis and pathological cardiac remodeling as well as other 
chronic inflammatory or degenerative disorders of ageing [26]. Cardiovascular, inflam-
matory and autoimmune conditions are more frequent in MDS patients compared to the 
normal population [27,28]. However, it remains unclear whether these are off-target or 
disease-driving effects. The switch from an activated to exhausted immunological tumor 
surveillance, referred to as immune subversion, is characteristic for neoplastic conditions 
and promotes further clonal expansion [29]. Although this immunological phenomenon 
needs further understanding, it opens the field for early therapeutic interventions aiming 
to revert immune subversion and reduce progression to higher-risk MDS or sAML. 
Recent translational studies suggest that dysregulation of the innate immunity and 
an associated hyper-inflammatory state contribute to the pathogenesis of lower-risk MDS 
[30]. Increased levels of cytokines, chemokines and growth factors have been observed in 
PB and BM of MDS patients and are associated with adverse clinical outcomes [31–33]. 
Furthermore, larger-scale epidemiologic studies showed that patients with autoimmune 
disorders have an increased risk of developing MDS [34,35]. Innate immune receptors, 
such as Toll-like receptors (TLRs), participate in the pathogenesis of several non-infec-
tious, inflammatory and autoimmune disorders [36]. Several studies suggest that a num-
ber of TLRs, as well as other signal transducers in this pathway, are overexpressed in a 
high proportion of MDS patients (40–80%) [30,37]. Although, the precise role of TLR-me-
diated signaling in MDS remains to be fully elucidated, in vitro and in vivo studies sug-
gest that this pathway is involved in the loss of progenitor cell function leading to im-
paired differentiation of HPSCs. In line with this, a recent study highlighted the crucial 
role for NLR family pyrin domain containing 3 (NLRP3) inflammasome in lower-risk 
MDS pathology and propagation of clonal HSPCs [38]. Inflammasomes are cytosolic in-
nate immune receptors that upon activation form caspase-1-activating multiprotein com-
plexes. These activate interleukin-1 cytokine members (IL-1β and IL-18) and initiate 
Gasdermin-D mediated pyroptosis, an inflammatory form of cell death [39,40]. Therefore, 
pyroptosis and immune subversion play mechanistically an important role in lower- and 
higher-risk MDS, respectively, and are currently under investigation as potential treat-
ment targets. 
3. General Aspects of MDS Patient Management 
The heterogeneity of MDS and the multimorbidity represent major challenges. The 
disease course may vary from chronic asymptomatic or minimal symptomatic cytopenia 
to rapid progression towards sAML. Therefore, correct diagnosis, disease- and patient-
based risk stratification are essential for an appropriate treatment plan. Experienced phy-
sicians, acting within interdisciplinary diagnostic and therapy review boards, should pref-
erentially be involved. Lower-risk MDS patients have a median survival of 3 to 8 years 
and mostly succumb to non-leukemic causes of death. These include mainly cardiovascu-
lar events, infections and other relevant comorbidities, being aggravated by cytopenia and 
inflammation. Thus, treatment in lower-risk MDS should improve symptomatic cytope-
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nia and optimize comorbidities aiming to improve quality of life (QoL) and delay pro-
gression [41,42]. Higher-risk MDS patients have a median survival of 1 to 3 years and die 
predominantly of complications related to sAML progression. The treatment aim in these 
patients is the reduction of progression and improvement of overall survival (OS) with 
minimal treatment-related toxicities [43,44]. 
4. Diagnostic Approach and Risk-Stratification 
In patients with suspected MDS, previous exposure to genotoxic agents (e.g., cyto-
toxic chemotherapy, radiation) should be evaluated, which indicates the presence of a 
therapy related myeloid neoplasm (t-MN). Younger MDS patients (<40 years) should be 
thoroughly screened for germline predispositions, which may be indicated by a family 
history of malignancies as well as immune or organ dysfunctions in first- and second-
degree relatives. The European Leukemia Net recommendation recognizes diagnostic 
procedures as “mandatory” (evaluation of PB smears and BM aspirate/biopsy with cyto-
genetic analysis), “recommended” (fluorescence in situ hybridization (FISH) and flow cy-
tometry), and “suggested” in specific circumstances (single-nucleotide-polymorphism 
(SNP), molecular diagnostics) [45]. Process-based indicators as measurable elements for 
quality of care are of increasing interest to enable assessment and comparison of the im-
pact of different health care environments on relevant MDS outcomes [46]. 
4.1. WHO Classification and Minimal Diagnostic Criteria for MDS 
MDS are diagnosed according to the updated classification of the WHO 2016 (Table 
4) [47]. Cytopenia and dysplasia remains the mainstay in the diagnosis of MDS; however, 
assessment of dysplasia is subjective with inter-individual variability (Table 5) [48]. Some 
patients with persisting cytopenia for at least 6 months may fail to fulfill these criteria. 
Therefore, an international working group proposed minimal diagnostic criteria and co-
criteria that define conditions with high suspicion for myeloid neoplasm or MDS. These 
include BM stem cell proliferation, aberrant immunophenotypic characteristics, clonality 
of myeloid cells as well as abnormal gene-expression profiles (Table 6) [23]. Cases that do 
not meet the co-criteria of clonality are classified as idiopathic cytopenia or dysplasia of 
undetermined significance (ICUS/IDUS) [49]. 








% RS of All 
Erythroid Cells in 
BM  
% Blasts in PB or 
BM 
AR: Auer Rods  
Conventional 
Cytogenetics 
   wtSF3B1 mSF3B1 BM PB AR  
MDS-SLD 1 1 or 2 <15 <5 <5 <1 -  
MDS-MLD 2 or 3 1–3 <15 <5 <5 <1 -  
MDS-RS-SLD 
 
1 1 or 2 ≥15 ≥5 <5 <1 -  
MDS-RS-MLD 
 
2 or 3 1–3 ≥15 ≥5 <5 <1 -  
MDS del(5q) 1–3 1 or 2 n.a. n.a. <5 <1 - 
Isolated del(5q) 




del(7) or −7  
MDS-EB-1 0–3 1–3 n.a. n.a. 5–9 2–4 -  
MDS-EB-2 0–3 1–3 n.a. n.a. 10–19 5–19 +  
MDS-U   <15 <5 <5 <1 -  
(a) 1% blasts 
in PB 
1–3 1–3 n.a. n.a. <5 1 3 -  
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(b) SLD with 
pancytopenia 








RCC 1–3 1–3 <15 ≤5 <5 <1 -  
1 Without previous cytotoxic treatment or germline predisposition for myeloid neoplasms; 2 Cyto-
penias: hemoglobin <100 g/L, thrombocytes <100 G/L, neutrophils <1.8 G/L, monocytes <1 G/L; 3 
One percent blasts in PB must be confirmed with a second measurement; 4 ≤15 RS corresponds to 
MDS-RS-SLD. CAVE: If ≥50% are erythroid precursors and ≥20% blast cells of non-erythroid-line-
age but <20% of all cells, this corresponds to MDS (MDS-SLD/MLD or EB) and not to AML M6 
erythroid/myeloidAR, Auer rods; BM: bone marrow; del(5q), loss of part of the long arm of chro-
mosome 5; EB, excess of blasts; MDS, myelodysplastic syndromes; MDS-U, myelodysplastic syn-
dromes unclassified; MLD, multi-lineage dysplasia; PB, peripheral blood; RCC, refractory cytope-
nia of the childhood; RS, ring sideroblasts; SLD, single lineage dysplasia; wt/mSF3B1, wild-type or 
mutated SF3B1. 
Table 5. Morphological characteristics of dysplasia [48]. 
Peripheral Blood 
- Erythrocytes: anisocytosis 
- Neutrophils: Pseudo-Pelger--Huët anomaly, cytoplasmic hypogranularity 
- Thrombocytes: anisocytosis, giant platelets 
Bone marrow 
- Dyserythropoiesis: nuclear budding, internuclear-bridging, karyorrhexis, multi-
nuclearity, megaloblastoid changes, ring sideroblasts, vacuolization, periodic 
acid-Schiff (PAS) positivity 
- Dysgranulopoiesis: small or unusually large size, nuclear hypo- or hypersegmen-
tation, decreased granules/agranularity, Pseudo-Chédiak--Higashi granules, 
Döhle bodies, Auer rods 
- Dysmegakaryopoiesis: micromegakaryocytes, nuclear hypolobation, multinucle-
ation 
Table 6. Minimal diagnostic criteria for the diagnosis of MDS ([23]). 
Criteria Diagnostic Test 
1. Mandatory criteria (both have to be fulfilled) 
Persistent cytopenia(s) for more than 4 
months *  
PB counts and morphological assessment 
Exclusion of other disease(s) that may cause 
cytopenia/dysplasia 
BM aspirate and biopsy, cytogenetics, flow 
cytometry, molecular genetics, other rele-
vant investigations ** 
2. MDS-defining criteria (at least one has to be fulfilled) 
Morphological criteria of dysplasia >10% in 
at least one cell lineages investigated in the 
BM 
PB, BM aspirate and biopsy 
Blasts 5–19% in BM or 2–19% in PB PB, BM aspirate and biopsy 
Ring sideroblasts ≥15% or  
≥5% with SF3B1 mutation 
Iron staining, sequencing 
MDS-defining cytogenetic alterations ***  
Conventional metaphase cytogenetics,  
interphase fluorescence in situ hybridiza-
tion,  
array comparative genomic hybridization  
3. Co-criteria (for patients with 1. but not 2., two have to be fulfilled) 
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Abnormal findings in histologic and/or  
immunohistochemical studies of support-
ing the  
diagnosis of MDS ****  
BM biopsy sections  
with immunohistochemistry  
Abnormal immunophenotype of BM cells 
with aberrant immunophenotype  
indicative for a monoclonal population 
Flow cytometry 
Clonality of myeloid cells revealing  
MDS-related mutations 
Molecular genetics, next generation se-
quencing 
If no major criterion is fulfilled, but the patient is likely to suffer from a clonal myeloid disease, co-
criteria should be applied and may help in reaching the conclusion that the patient has a myeloid 
neoplasm resembling MDS or will develop MDS. In this diagnostic setting, repeated bone marrow 
investigations during follow-up may be required to arrive at a final diagnosis of MDS. BM: bone 
marrow; PB: peripheral blood. * Cytopenia defined by local institutional reference values. ** Inves-
tigations depend on individual criteria and should include serum electrophoresis with immuno-
fixation, erythropoietin and tryptase. *** Cytogenetic alterations indicative of MDS, as defined by 
WHO. **** i.e., clusters of abnormally localized immature precursors (ALIP); clusters of CD34+ 
blast cells; dysplastic micromegakaryocytes detected by immunohistochemistry (≥10% dysplastic 
megakaryocytes). 
4.2. Role of NGS in MDS Diagnosis, Follow-Up and Risk-Stratification 
Targeted NGS panels offer the analysis of hotspot mutations in 40–50 genes at a sen-
sitivity of ~5% VAF [50,51]. This allows the identification of clonal hematopoiesis at early 
stages of development. At the same time, it becomes increasingly difficult to distinguish 
age-related changes with a favorable course from conditions that progress more rapidly 
to overt hematological malignancies. The risk for progression depends on the affected 
genes (higher-risk as compared to lower-risk mutations), the number of SLADMs and the 
clonal burden (>10% VAF). Patients with unclear cytopenia and higher-risk SLADMs have 
a similar probability of survival as lower-risk MDS patients (Figure 2) [52]. In the case of 
stable clonal hematopoiesis, thorough clinical and laboratory observation may be indi-
cated every 3−6 months, with repeated BM assessment at signs of progression (worsening 
cytopenia, occurrence of cytosis, blasts or precursors in PB) [45]. NGS has revolutionized 
diagnostics, risk stratification and treatment monitoring in MDS. However, controversies 
and challenges remain on its rational use in MDS [53–56]. Genes can also be mutated con-
stitutionally (germline) and may indicate the presence of predisposition syndromes for 
myeloid malignancies (Table 1). NGS has not only gained importance in identifying the 
clonal origin of unclear cytopenias, but it also allows us to identify potential therapeutic 
targets (SF3B1, TP53, IDH1/2). Moreover, it plays an important role in prognosis as well 
as monitoring after allogeneic hematopoietic stem cell transplantation (allo-HCT) [53,54]. 
More recently, genomic features of cytogenetics and NGS have been integrated for next-
generation disease classification and prognostication based on biological information [57]. 
Sequential NGS analysis may gain importance for the assessment of clonal composition 
during treatment and for the genetically inferred selection of targeting compounds to re-
fractory subclones in the near future. 




Figure 2. Predictive mutations for myeloid malignancies (adapted from [52]). (A) Higher-risk SLADMs (spliceosome genes 
and DAT plus mutations) with their specificity for development of myeloid malignancy over 5 years. (B) Variant-allele 
frequency (VAF) cut-offs with their corresponding positive and negative predictive values (PPV, NPV) for evolution to 
myeloid malignancy over 5 years. PPV and NPV at the bottom of the table are represented for a cut-off VAF at 0.1. (C) 
Cumulative probability for evolution to myeloid malignancy for high- (green), low-predictive (red) and unmutated (blue) 
individuals. (D) Cumulative probability of survival for individuals with clonal cytopenia of undetermined significance 
(CCUS) with high-predictive mutations (blue) and lower-risk MDS (red: LR-MDS). 
4.3. Hypoplastic MDS and Aplastic Anemia 
The presence of unexplained cytopenia accompanied by signs of dysplasia in the PB 
or BM and, at later stages, increase of myeloid blasts, is seminal for the diagnosis of MDS. 
This is especially challenging in conditions with hypoplastic BM (cellularity < 30%), re-
ferred to as hypoplastic MDS (hMDS) and occurring in 5–10% of all MDS cases [4]. When 
cytomorphology is not sufficient to confirm or exclude hMDS, cytogenetics may identify 
clonality with detectable chromosomal abnormalities in ~50% of cases. NGS increases the 
sensitivity for the identification of clonality. However, SLADMs can also be found in 
aplastic anemia (AA), thus making the distinction form hMDS more challenging, adding 
more complexity in finding the correct diagnosis. An integrated cyto-histologic/genetic 
score (hg-score) has been recently developed to facilitate distinction between AA and 
hMDS (Table 7) [52,58]. Other conditions may mimic hMDS or AA and etiologies can be 
multifactorial in elderly patients, such as transient aggravation of cytopenia during infec-
tions or drug-exposure in patients with CHIP. Delay in recovery after these intercurrences 
suggest conditions that are more advanced, directing further investigations to exclude 
MDS. 
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Table 7. Integrated cyto-histologic/genetic score for distinction of non-malignant bone-marrow 
failure syndromes and hypoplastic MDS. 
Requisite Criteria Score 
BM blasts AND/OR CD34+ cells ≥5% 2 
BM blasts AND/OR CD34+ cells 2–4% 1 
Fibrosis grade 2–3 1 
Dysmegakaryopoiesis 1 
Co-criteria 
Ring sideroblasts ≥15% 2 
Ring sideroblasts 5–14% * 1 
Severe dysgranulopoiesis 1 
Karyotype (co-criterion) 
Presumptive cytogenetic abnormality * 2 
Somatic mutation (co-criterion) 
Specific high-risk mutation pattern ** 1 
* According to WHO 2016 criteria (Table 4) [47]. ** According to Malcovati et al. [52]; BM: bone 
marrow; hg-score: cyto-histologic/genetic score; ROC analysis confirmed that a cutoff hg-score of 2 
is associated with the highest percentage of correctly classified hMDS cases (AUC 0.89, p < 0.001). 
4.4. Disease-Based Risk Stratification 
Different scoring systems support clinical decision making by estimating the risk for 
progression to sAML and OS. The International Prognostic Scoring System (IPSS) [59], the 
revised IPSS (IPSS-R) [60] and the WHO Prognostic Scoring System (WPSS) [61] are the 
most widely used scoring systems. The WPSS seem to be less important according to a 
recent consensus for defining relevant indicators [46]. Lower-risk MDS is generally char-
acterized by mild and single-lineage cytopenia, blasts < 5% and the presence of a normal 
karyotype or favorable cytogenetic aberrations. In contrast, more severe and multi-linage 
cytopenia, transfusion-dependency, excess of blasts as well as poor-risk or complex cyto-
genetic aberrations characterize higher-risk MDS. Somatic mutations in TP53, EZH2, 
ETV6, RUNX1, ASXL1, SRSF2, U2AF1, RAS-pathway and JAK2 with VAF ≥2% provide 
independent prognostic information, but are not yet integrated in current scoring systems 
[13]. However, information about the mutation profile in individual patients can be clini-
cally meaningful and further supports the implementation of targeted NGS analysis, par-
ticularly for younger MDS patients. 
4.5. Patient-Based Risk Stratification 
Patient-based risk stratification considers age, comorbidities, performance status and 
frailty (reduced physical fitness) to estimate their impact on treatment-related mortality. 
Karnofsky and ECOG performance scores are broadly applied to assess residual func-
tional ability [45]. Using individualized patient-based risk-stratification, MDS patients are 
classified as fit (good performance status without limiting comorbidities) or unfit (poor 
performance status and/or multiple comorbidities) for intensive treatment approaches, 
including standard induction chemotherapy or allo-HCT. The hematopoietic stem cell 
transplant-specific comorbidity index (HCT-CI) allows the prediction of non-relapse mor-
tality in the allo-HCT setting [62]. The MDS-specific comorbidity index (MDS-CI) is a sim-
plified form of the HCT-CI (cardiac, hepatic, pulmonary, renal disorders and previous 
solid tumors) and more frequently used in transplant ineligible MDS patients [63]. MDS-
specific frailty index adds independent prognostic information to the IPSS-R score [64]. 
Patient-based risk factors have an independent impact on OS of elderly patients with MDS 
and should be used together with disease-based risk stratification [46,65]. 
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4.6. Patient-Reported Outcomes (PROs) 
The Quality of life (QoL) and symptom-burden including pain/discomfort, immobil-
ity, anxiety/depression, and most commonly fatigue are inferior in MDS patients com-
pared to age-matched controls [8]. Fatigue by itself is frequent in MDS and has a negative 
prognostic impact on survival [66]. A variety of QoL assessment tools are available, in-
cluding the European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire (EORTC QLQ-C30), EuroQol 5 Dimension (EQ-5D), the Functional Assess-
ment of Cancer Therapy Anemia Scale (FACT-An) and the MDS-specific Quality of Life 
in Myelodysplasia Scale (QUALMS) [67–70]. These instruments integrate functional fac-
tors (physical, role, cognitive, emotional, and social), symptoms (fatigue, pain, nausea and 
vomiting), global health as well as QoL items. Incorporating patient-reported outcomes 
(PROs) is generally considered relevant for individualized MDS treatment. However, a 
generally accepted gold standard and the therapeutic impact remains currently unclear 
[46]. Moreover, many tools seem to be impracticable for the daily routine and simplified 
screening tools or instruments focusing on self-sufficiency in nutrition or mobility may be 
valuable alternatives [71]. 
5. Therapeutic Approach 
Experienced physician and interdisciplinary boards should be involved in the assess-
ment of MDS patient with symptomatic cytopenia or unexplained inflammatory condi-
tions. This is important due to disease complexity, interfering comorbidities, and timely 
selection of higher-risk MDS patients being eligible for allo-HCT. Fluctuating cytopenias 
may be the initial manifestation of clonal hematopoiesis. However, patients with unchar-
acterized systemic autoinflammatory manifestations may also present with SLADMs at 
high VAFs, as primary manifestation of clonal hematopoiesis or even MDS [40]. New ther-
apeutic options and clinical trials are urgently needed, especially in elderly patients with 
refractory conditions [72]. Therefore, symptomatic patients should be referred to experi-
enced MDS centers, included in prospective registries/biobanks, and offered participation 
to clinical trials, whenever possible. The therapeutic approaches for lower- and higher-
risk MDS are summarized in Figure 3A and 3B, respectively, and an overview on the treat-
ment landscape can be found in Figure 4.  
5.1. Lower-Risk MDS Patients 
5.1.1. Watchful Observation and General Supportive Treatment 
Life expectancy of asymptomatic MDS patients >70 years of age with single lineage 
dysplasia (SLD) or del(5q) does not substantially differ from an age-matched population 
[61]. Therefore, watchful observation is adequate for most asymptomatic MDS patients. 
Despite increasing knowledge of high-risk genetic constellations [13,73,74], no prospec-
tive clinical trial could demonstrate any benefit for early interventions in these patients, 
and supportive treatment is still the mainstay of lower-risk MDS patients. Non-disease 
related factors like nutrition and functionality are often overlooked or not specifically ad-
dressed despite their prognostic importance [75]. The same is true for psychological and 
social distress that may influence compliance and treatment adherence. 
5.1.2. Treatment of Anemia 
Transfusions of red blood cells (RBC) can improve symptomatic anemia immedi-
ately. A hemoglobin threshold <80 g/L is often applied but should be individualized de-
pending on age, comorbidities and symptoms. Repeated transfusions can cause alloim-
munization and iron overload. Iron chelation therapy is usually recommended in patients 
with >20 transfused RBCs, serum ferritin > 1000 µg/L or other signs of iron-overload with 
a life expectancy >1 year or candidates for allo-HCT [45,76,77]. Yet, the indication remains 
somehow controversial, since a recently performed prospective clinical trial with defer-
asirox could only show a reduction of event-free survival (cardiovascular events). Due to 
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low accrual, the trial had to be closed prematurely and the power was not sufficient to 
show a reduction in OS [46,78–83]. Erythropoietin stimulating agents (ESA) can improve 
symptomatic anemia and delay transfusions. Best responses can be achieved in lower-risk 
MDS patients with an endogenous serum erythropoietin <500 U/L and low transfusion 
burden (≤4 RBCs over 8 weeks) (Nordic criteria) [45,84,85]. While all erythropoietin agents 
seem to be similarly efficient, randomized, placebo-controlled trials exist only for epoetin 
alpha (450 IU/kg every week) and darbepoetin alpha (300–500 µg every 2 to 3 weeks) 
[86,87]. Responses range around 40–50% with a median duration of 1–2 years and poor 
prognosis for ESA refractory patients [88]. Addition of granulocyte-colony stimulating 
factor (G-CSF) to ESA in anemic MDS patients is generally recommended, but remains 
controversial, as current data is limited for an additional efficacy, if added to full-dose 
ESA [89]. Moreover, the combination of ESA with lenalidomide (LEN) seems to increase 
the response-rates in ESA refractory lower-risk MDS patients [90]. Luspatercept (LUSPA) 
is a first in class erythroid maturating agent (EMA) interfering with aberrant TGFβ and 
SMAD2/3 signaling. It has recently been approved by the American and European medi-
cal agencies, based on results from phase 2/3 trials in transfusion dependent MDS patients 
with ring sideroblasts (RS) or SF3B1 mutations, refractory or not eligible for ESA [91,92]. 
5.1.3. Treatment of Thrombocytopenia 
Thrombocyte concentrates (TC) are generally transfused prophylactically, if platelets 
fall <10–20 G/L considering additional factors favoring bleeding (fever or mucositis) or 
<50 G/L in patients requiring strict anticoagulation [93,94]. While these thresholds are 
mainly based on experiences from chemotherapy-induced thrombocytopenia, physicians 
need to be aware of endogenous thrombocyte dysfunctions in MDS favoring bleeding 
even above such thresholds [95]. Due to short platelet half-life, TC have to be transfused 
at least weekly or more frequent in conditions of increased consumption (infections) and 
may be associated with transfusion-related complications (immunization, febrile reac-
tions). Thrombopoietin receptor agonists (TPO-RAs) are established in immunthrombo-
cytopenia (ITP) and represent a possible alternative in MDS patients. Their broader appli-
cation is hampered by an increase of bone-marrow fibrosis and blast counts observed in 
clinical trials but, fortunately, without impact on leukemic progression [96,97]. Therefore, 
TPO-RAs might be safe in lower-risk, but are still not licensed for MDS patients in many 
countries [46]. Interestingly, recent data also showed an improvement on other cell lines 
in AA and a combined treatment with immune-suppressive agents might be of value in 
for hMDS [98]. 
5.1.4. Treatment of Neutropenia and Infection Prophylaxis 
Isolated neutropenia is rare and challenging to treat in lower-risk MDS patients. Most 
patients with neutropenia have higher-risk disease and may qualify for HMA or more 
intensive treatment. Evidence is currently insufficient for primary prophylaxis with either 
G-CSF or anti-infective treatment in patients with severe neutropenia (<0.5 G/L) [46]. Sec-
ondary prophylaxis with antibiotics, antimycotics or antiviral substances can be made on 
an individual basis. Even though it has not been systematically investigated, vaccinations 
against COVID-19, influenza and pneumococci are generally recommended in MDS pa-
tients, although the individual immunological response may be very variable [57]. 
5.1.5. Disease Modifying Treatments in Specific Subsets of Lower-Risk MDS 
In transfusion-dependent, lower-risk MDS with del(5q), LEN can provide sustained 
transfusion independence in two thirds and cytogenetic responses in half of all treated 
patients, with median duration of transfusion independence of 1–2 years [99]. Patients 
with mutations in TP53 have shorter response durations and OS [100]. In non-del(5q) MDS 
patients, the efficacy of LEN seems to be more modest and short lived, but additional 
benefits have been reported for combined treatment with ESA [90]. Between 5–10% of 
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MDS present with hypoplastic BM, and long-lasting responses have been reported in 
16−67% of cases treated with antithymocyte globulin (ATG) combined with cyclosporin A 
(CyA) with or without TPO-RAs [101]. 
5.1.6. Hypomethylating Agents 
Lower risk MDS patients with predominant neutropenia, multiple cytopenias or who 
are refractory to first line treatment with growth factors, maturating agents, LEN or other 
immune-modulating treatments are potential candidates for hypomethylating agents 
(HMA). HMAs are used in the formal lower-risk setting in the US, but are not licensed in 
Europe for this indication. Recently, a randomized study compared the safety and efficacy 
of low-dose HMA (decitabine 20 mg/m2 i.v. d1–3 or azacytidine 75 mg/m2 i.v. or s.c. d1–
3) in lower-risk MDS. The treatment was well tolerated with promising responses ranging 
between 50–70% in selected patients, but warrants further investigations [102]. Lower-risk 
MDS patients with symptomatic and refractory cytopenia as well as those with high-risk 
features have an unmet need for novel treatment options and should be offered clinical 
trials. 
5.2. Higher-Risk MDS Patients 
5.2.1. Hypomethylating Agents 
HMAs comprise the pyrimidine nucleoside analogs 5-azacytidine (AZA) and 5-aza-
2′deoxycytidine/decitabine (DEC), the latter only being approved for MDS treatment in 
the US [103,104]. In a phase 3 trial in higher-risk MDS patients not eligible for allo-HCT, 
AZA demonstrated significantly higher responses and survival benefit (median OS 24.5 
vs. 15.0 months) compared to conventional care regimens with hydroxyurea or low-dose 
cytarabine (LD-AraC) [103]. Due to delayed HMA treatment response, at least 6 cycles 
should be administered before considering resistance. HMA remains inferior to more in-
tensive induction chemotherapy followed by allo-HCT, for which, however, only younger 
and fit patients are eligible [105]. In MDS patients with complex karyotype and lacking of 
a stem cell donor, HMA should be preferred due to higher CR rates and lower toxicity 
compared to intensive chemotherapy [106]. Lower HMA response rates have been de-
scribed in patients with poor performance status (ECOG > 2), high transfusion depend-
ency (>4 RBCs over 8 weeks), higher number of BM blasts (>15%), circulating blasts, higher 
cytogenetic risk scores and TP53 mutation. Mutations in epigenetic regulators such as 
TET2, EZH2 and DNMT3A seem to be associated with better responses [107–110]. Thus 
far, robust predictive markers for HMA response are lacking. Recently, the FDA granted 
approval for the combination of oral decitabine and cedazuridine (ASTX727, Inqovi®), a 
cytidine-deaminase inhibitor, as treatment for MDS or CMML, showing equal pharmaco-
kinetic and –dynamic characteristics like the i.v. formulation [111]. As HMA does not sig-
nificantly modify the clonal disease composition, treatment should be continued as long 
as tolerated in the absence of signs of progression. Patients refractory to HMA have an 
unmet need for novel treatments and should be treated within clinical trials. 
5.2.2. Induction Chemotherapy 
Cytoreductive induction treatment with AML-based chemotherapy before allo-HCT 
is the mainstay for young and fit higher-risk MDS with ≥10% BM blasts [112]. Alternative 
induction treatments are fixed liposomal combinations of danorubicine/cytarabine (CPX-
351, Vyxeos®) [113] or HMA in elderly patients that are deemed to be eligible for allo-
HCT, but are at increased risk for toxicity. However, appropriately designed clinical trials 
to answer the question of the most suitable induction chemotherapy for MDS patients are 
missing. Good prognostic factors for allo-HCT are younger age, good performance status 
and favorable cytogenetics [114]. For higher-risk MDS patients with <10% marrow blasts, 
it remains controversial whether HMA induction is required or if it is better to proceed 
directly to allo-HCT [112]. For patients without a suitable donor and ≥10% marrow blasts, 
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one course of induction chemotherapy may be recommended followed by HMA mainte-
nance [45]. Patients with poor-risk cytogenetics or TP53 mutations should be preferen-
tially treated with HMA, as toxicity predominates the limited responses to standard chem-
otherapy [106]. These patients should be offered induction treatments within clinical tri-
als. 
5.2.3. Allogeneic Hematopoietic Stem Cell Transplantation 
Allo-HCT remains the only curative treatment option for fit and higher-risk MDS 
patients up to 75 years of age [112]. As non-relapse mortality depends on comorbidities, 
the HCT-CI is relevant to estimate non-relapse mortality and the selection of appropriate 
candidates [115]. Maximal benefit of allo-HCT is associated with transplantation in pa-
tients in the higher-risk disease state, whereas lower-risk patients with poor-risk cytoge-
netic/genetic features, profound cytopenias, and high transfusion burden may also benefit 
from transplantation [116]. Age, disease status and molecular gene status are the most 
important predictive factors for OS after allo-HCT, with TP53, RAS pathway, ASXL1, 
RUNX1 mutations associated with a higher risk of relapse [117–120]. Furthermore, NGS-
based detection of MRD before conditioning is associated with earlier relapse and might 
guide the selection of myeloablative or reduced-intensity conditioning [121]. Reduced-
intensity conditioning regimens are mainly considered for patients with comorbidities or 
age >50 years; however, prospective randomized clinical trials have not provided robust 
evidence for the optimal conditioning regimen [122,123]. Maintenance therapy and MRD-
based consolidation therapy should be offered after allo-HCT, whenever possible, in the 
context of clinical trials [112]. 
6. Ongoing Clinical Trials with Targeting Compounds 
The ongoig clinical trials with targeting compounds in lower- and higher-risk MDS 
are summarized in Table 8. 
6.1. Lower-Risk MDS 
LUSPA is currently investigated as first-line treatment in transfusion dependent, 
ESA-naïve, lower-risk MDS patients, independent of RS or SF3B1 mutational status [124]. 
Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor 
(HIF-PHI), which modulates the oxygen-sensing pathway, and increases EPO and eryth-
ropoietic output in patients with chronic kidney disease [125]. This compound is currently 
investigated in a placebo-controlled, phase 3 clinical trial for transfusion-dependent MDS 
patients in first line [126]. Higher telomerase activity and telomerase reverse transcription 
(TERT) expression have been identified in mononuclear cells as poor prognostic features 
in MDS [127–129]. This provides the scientific rationale for testing the therapeutic efficacy 
of the telomerase inhibitor, imetelstat, in MDS. It is a 13-mer oligonucleotide that specifi-
cally targets the RNA template of human telomerase, which has been tested in various 
preclinical studies [130–132]. In a recent phase 2 clinical trial, imetelstat increased hemo-
globin and reduced transfusion requirements in ESA refractory or ineligible MDS pa-
tients. An international phase 3 clinical trial is currently ongoing [132]. Based on the im-
portance of pyroptosis in MDS, an array of inhibitors of S100A8/9, NLPR3 and IL1 have 
been investigated in pre-clinical models and may enter clinical trials soon.  







Figure 3. Treatment algorithm for lower- and higher-risk MDS. Yellow boxes highlight areas with 
an unmet clinical need in in lower (A) and higher-risk MDS (B). High-risk (HR) mutations com-
prise: ≥3 SLADMs or single mutations in TP53, RUNX1, ASXL1, ETV6, EZH2, SRSF2, U2AF1, RAS-
pathway and JAK2 with VAF ≥2% [13,73,74]. Allo-HCT: allogeneic hematopoietic stem cell trans-
plantation; AML-CTX: AML-based chemotherapy; ATG: antithymocyte globulin; BM: bone mar-
row; CSA: Cyclosporine A; CyG: cytogenetics; ESA: erythropoietin stimulating agent; HMA: hy-
pomethylating agent; HR: high-risk mutations; mSF3B1: mutated SF3B1; PB: peripheral blood; PS: 
performance status; RBC: red blood cell concentrate; RS: ring sideroblasts; sEpo: serum erythro-
poietin; TPO-RA: thrombopoietin receptor agonist. 




Figure 4. Treatment landscape in MDS. Treatment can affect normal (left) and clonal hematopoie-
sis (right). SLADMs: somatic leukemia-associated driver mutations; ESA, erythropoietin stimulat-
ing agent; ICI, immune checkpoint inhibitors; G-CSF, granulocyte colony stimulating factor; 
HMA, hypomethylating agents; IST, immune suppressive treatment (CyA/ATG); LEN, lenalido-
mide; LUSPA, luspatercept; TPO-RA: thrombopoietin receptor agonists; VEN, venetoclax. 
6.2. Higher-Risk MDS 
Spliceosome genes are frequently affected by SLADMs and are mutually exclusive 
with other spliceosome mutations. Preclinical studies suggest a synthetic lethality of 
spliceosome inhibitors and a first in class oral spliceosome modulator (H3B-8800) is cur-
rently being investigated in higher-risk MDS patients [133–135]. Prolonged HMA expo-
sure may improve the efficacy, as these drugs act in the S-phase of the cell cycle. Strategies 
to achieve this aim include the developments of cytidine deaminase resistant HMAs (gua-
decitabine) [135–137], fixed dose combinations of oral decitabine with the cytidine deam-
inase inhibitor, cedazuridine [111,138] and oral formulations of AZA (CC-486) [139,140]. 
The FDA has recently approved oral HMA, CC-486, for maintenance therapy in elderly 
AML patients, while cedazuridine/decitabine received approval as first line treatment in 
MDS in the US but not in Europe. These promising agents are currently investigated alone 
and in combination with different agents in various MDS settings. Combination partners 
with HMA include immune checkpoint inhibitors (ICI), such as antibodies to CD47 (ma-
grolimab) [141], TIM3 (sabatolimab) [142] and CD70 (cusatuzumab) [143]. Thus far, other 
ICI targeting PD1, PD-L1 or CTLA4 have shown only limited activity alone and in combi-
nation with HMA in higher-risk MDS patients. The BCL2-inhibitor, venetoclax, in combi-
nation with HMAs or LD-AraC, has shown substantial activity and has advanced to the 
standard of care in first-line treatment of elderly patients with AML [144]. This combina-
tion has showed promising efficacy also in MDS and is currently further investigated in 
the first-line and HMA relapsed/refractory settings [145–147]. Nevertheless, the manage-
ment of hematological toxicity remains a major challenge and requires careful monitoring 
of patients, dose adaptations and supportive treatment with growth-factors, antibiotics, 
and antimycotics. Neural-precursor-cell-expressed developmentally down-regulated 8 
(NEDD8) is an ubiquitin-like protein involved in various DNA repair mechanisms and 
causes synthetic lethality to cancer cells. In a phase 2 trial in patients with unfit, high-risk 
MDS/CMML or low-blast count AML, a NEDD8-activating enzyme (NAE) inhibitor 
(pevonedistat) in combination with HMA showed an improvement of progression-free 
survival compared to HMA monotherapy [148]. Results from an ongoing phase 3 trial 
shall be published soon [149]. The discovery of SLADMs has opened a completely new 
era for risk stratification and patient selection for target therapies. A promising compound 
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is APR-246 (eprenetapopt), a reconfirming agent of mutated TP53, which has shown un-
anticipated responses in TP53 mutated AML and MDS patients [150–153]. IDH1 and IDH2 
mutations occur in ~10% of MDS patients. The corresponding inhibitors (ivosidenib and 
enasidenib) have shown encouraging results in AML patients and are currently tested in 
higher-risk MDS setting [154–157]. Other target therapies for higher-risk MDS, adopted 
from AML treatment, include the FLT-3 inhibitors (midostaurin, gilteritinib, and quizar-
tinib), which are investigated in phase 2 clinical trials [158–160]. Cellular-based immune-
therapies are of increasing interest. Chimeric antigen receptor (CAR) T-cell therapy tar-
geting CD123 successfully eliminated MDS stem cells both in vitro and in patient-derived 
xenografts [161]. Bispecific CD3/CD123 or CD3/CD33 antibodies [153,161,162] as well as 
personalized adoptive cell therapy, which selects, immunizes and expands T-cells against 
MDS-specific mutations and targets patient-specific tumor cell neo-antigens, may be 
promising [163]. 
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Table 8. Overview on novel targeted and immunotherapeutic options for patients with MDS. 
Compound Study Design Efficacy *  Safety * NCT 
Erythropoiesis maturating agents 
TGFβi 
luspatercept 
Phase 3 (ongoing), open-label, randomized 
study: efficacy and safety of luspatercept (ACE-
536) versus epoetin alpha for the treatment of 
anemia due to IPSS-R very low, low or interme-
diate risk according to IPSS-R MDS in ESA na-
ïve subjects requiring red blood transfusions 
(COMMANDS) 
ongoing 
38% vs. 13% TI for 8 weeks or 
longer 
AE: 
- similar grade 3/4: 42% vs. 45%, 
5% doses reduction  
- frequent: fatigue, diarrhea, asthe-
nia, nausea,  
- dizziness, back pain 
NCT03682536 
[124] 
Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHi) 
roxadustat  
(FG-4592) 
Phase 3, randomized double-blind placebo-con-
trolled study investigating the efficacy and 
safety of roxadustat (FG-4592) for treatment of 
anemia in patients with lower risk MDS with 






Phase 2/3 (phase 3 part ongoing), double-blind, 
randomized study to evaluate imetelstat 
(GRN163L) versus placebo in transfusion-de-
pendent subjects with IPSS low or intermediate-
1 risk MDS that is relapsed/refractory to ESA 
treatment (IMERGE) 
TI in 8- and 24-week: 37%, respec-
tively 23%, median duration of 65 
weeks 
phase 3 ongoing 
AE:  
- cytopenias, typically reversible 





Phase 1 (ongoing), open-label trial to evaluate 
the safety, pharmacokinetics and pharmacody-
namics of splicing modulator H3B-8800 for sub-
jects with MDS, AML and CMML  
decreased RBC or TC requirement 
in 14% 
AE: 
- diarrhea: 75% 
- nausea: 37% 
- fatigue: 28% 
- vomiting: 27% 
NCT02841540 
[134,135] 







Phase 1/2, dose escalation, dose escalation, ran-
domized study of two regimens of SGI-110, in 
subjects with intermediate or high-risk MDS or 
AML  
ORR 40% with 60 mg/m2 d1-d5 
q28d 
ORR 55% with 90 mg/m2 d1-d5 
q28d 
AE: 
- febrile neutropenia: 11% 
- pneumonia: 7% 
- anemia: 3% 
- thrombo- cytopenia: 3% 







Phase 3, randomized, open-label study of SGI-
110 versus treatment choice in adults with MDS 
or CMML previously treated with hypomethyl-
ating agents 
primary endpoint (OS): no statisti-
cally significant improvement sec-
ondary endpoints: analysis ongo-
ing  







Phase1 (ongoing), multi-phase, dose-escalation 
followed by an open-label, randomized, 
crossover study of oral ASTX030 versus 
subcutaneous  
azacytidine in subjects with MDS, CMML or 
AML  
parenteral and oral AZA + CDZ 
similar pharmacokinetic profiles 








Phase1/2 pharmacokinetic guided dose-
escalation and dose-confirmation study of 
ASTX727 (oral cytidine deaminase inhibitor 
E7727 with oral  
decitabine) in subjects with MDS 
no difference in pharmakokinetics, 
pharmacodynamics and efficacy 
between p.o. and i.v. formulations 
similar between p.o. und i.v.  
NCT02103478 
[111] 
Immune checkpoint inhibitors 





Phase 1b Trial of magrolimab monotherapy 
versus in combination with azacytidine in 
patients with hematological malignancies 
TI: 58% (MDS), 64% (AML) 
objective response (CR, marrow 
CR, HI): 91% (MDS) 
AE:  
- anemia: 38% 
- neutropenia: 19%, 
- thrombocytopenia: 18% 






Phase 1b, multi-arm, open-label study of 
PDR001 and/or MBG453 in combination with 
decitabine in patients with AML or high risk 
MDS 
AML: ORR 41.2% 
MDS: ORR 62.9% 
AE:  
Grad 3/4 (AML/MDS):  
- thrombocytopenia (45.8%, 51.2%) 
- neutropenia (50%, 46.1%) 
- febrile neutropenia (29.2%, 41%) 
- anemia (27.1%, 28.2%) 








Phase 1b/2 (ongoing), dose escalation study 
evaluating the safety and pharmacokinetics of 
venetoclax in combination with azacytidine in 
subjects with treatment-naïve higher-risk MDS 
18 months: OS 74%, HI 50%  
AE, grade 3/4: 
- neutropenia (68%) 
- febrile neutropenia (46%) 
- thrombocytopenia (39%) 






Phase 1b study (ongoing) evaluating the safety 
and pharmacokinetics of venetoclax as a single-
agent and in combination with azacytidine in 
subjects with relapsed/refractory MDS 
median FU 4.7 months: 
- monotherapy: ORR 7%, 
SD 75%,  
- PFS 3.4 months, OS 6 
months 57%  
Grade 3/4: 
- neutropenia (41%) 
- febrile neutropenia (17%) 
- pneumonia (13%) 
- thrombocytopenia (30%) 
NCT02966782 
[147] 
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- combination: ORR 50%, 
SD 31%,  
- PFS/OS not reached   
- anemia (15%) 
NEDD8i  
pevonedistat 
Phase 2, randomized, controlled, open-label, 
study of the efficacy and safety of pevonedistat 
plus azacytidine versus single-agent azacytidine 
in patients with higher-risk MDS, CMML and 
low-blast AML   
Combination vs. single-arm 
- OS 23.9 versus 19.1 
months 
- ORR 79.3% vs. 56.7% 
- CR¹ 51.7% versus 26.7%  
Grade 3/4 adverse events similar  
(69% vs. 63% in single-arm) 
- neutropenia 33% vs. 27% 
- febrile neutropenia 26% vs. 29% 
- thrombocytopenia 19% vs. 23% 





Phase 3, randomized, controlled, open-label, 
study of pevonedistat plus azacytidine versus 
single-agent azacytidine as first-line treatment 
for patients with Higher-Risk MDS, CMML or 




TP53 reconforming agents 
eprenetapopt 
(APR-246) 
Phase 1b/2 (ongoing) study to evaluate the 
safety and efficacy of APR-246 in combination 
with azacytidine for the treatment of TP53 
mutant myeloid neoplasms 
ongoing 
Grade 3/4 (phase 1b): 
- neutropenia 42% 










Phase 1, open-label, dose-escalation and 
expansion, safety, pharmacokinetic, 
pharmacodynamic, and clinical activity study of 
orally administered AG-120 in subjects with 
advanced hematologic malignancies with an 
IDH1 mutation 
CR² plus CRh²: 42.4% 
CR² 30.3% 
FU 23.5 months:  
median OS 12.6 months  
TI in 9 of 21 TD (42.9%)  
IDH1 mutation clearance in 9/14 
patients  
AE: 
- All grades: diarrhea (53%), 
fatigue (47%), nausea   
- (38%), decreased appetite (35%), 
DS (18%)  
- Grade ≥ 3 (9%): DS, QTc-
prolongation, febrile  
- neutropenia, diarrhea (did not 







Phase 1/2 (ongoing), open-label, dose-escalation 
and expansion, safety, pharmacokinetic, 
pharmacodynamic and clinical activity study of 
orally administered AG-221 in subjects with 
advanced hematologic malignancies with an 
IDH2 mutation 
phase 1: ORR 53% 
median duration 9.2 months 
OS 16.9 months 
phase 2 ongoing 
Grade 3/4 (phase 1): 
- indirect hyperbilirubinemia 
(35%), pneumonia  
- (29%), thrombocytopenia (24%), 
tumor lysis  
- syndrome (18%), sepsis (12%), 
atrial flutter (12%), 
- cerebral hemorrhage (12%), 
mental status change 
- (12%) 










Phase 1/2 study of the combination of 
quizartinib (AC220) with 5-azacytidine or low-
dose cytarabine for the treatment of patients 
with AML and MDS 
quizartinib/AZA-arm vs 
quizartinib/LD-AraC-arm: 
- previously untreated 
patients, 
CRc: 87% vs. 74% 
OS: 19.2 vs. 8.5 
months 
- previously treated patients 
CRc: 64% vs. 29% 
- OS: 12.8 vs. 4 months  
AE grade 3/4, quizartinib/AZA-arm vs.  
quizartinib/LD-AraC-arm: 
- neutropenia: 5% vs. 42% 
- febrile neutropenia: 40% vs. 36% 
- anemia: 0% vs. 15% 
- thrombocytopenia: 13% vs. 30%  
- pneumonia: 28% vs. 48%  
- hypokalemia: 33% vs. 9% 








Phase 1/2, first in human, dose escalation study 
of MGD006, a CD123 x CD3 DART® bi-specific 
antibody based molecule, in patients with 
relapsed or refractory AML or intermediate-
2/high risk MDS 
CR/CRh: 26.7% 
median OS 10.2 months 
ORR (CR/CRh/CRi): 30% 
most frequent AE:  
- infusion-related reactions (IRRs) 
and cytokine release syndrome 





A Phase 1 first-in-human study evaluating the 
safety, tolerability, pharmacokinetics, 
pharmacodynamics and efficacy of AMG 330 
administered as continuous intravenous 
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* Efficacy and safety data are extracted from published studies in AML/MDS according to the references. CR ¹: complete remission/HI: hematological 
improvement per International Working Group (IWG) 2006 criteria for myelodysplastic syndromes (MDS), CR ²: complete remission according to 
IWG 2003 response criteria for AML, CRc: composite response (CR ² + CRi + CRp + CRh), CRi: CR ² with incomplete hematologic recovery, CRh: 
CR ² with partial hematological recovery (bone marrow myeloblasts of <5% combined with both absolute neutrophil count >500/µL and platelet 
count >50 × 109/L, CRp: CR ² without platelet recovery, DS: differentiation syndrome, FU: follow-up, ORR: overall response rate, OS: overall survival, 
PFS: progression free survival, RBC: red blood cells, SD: stable disease, TI: transfusion independency, TD: transfusion dependent. 
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7. Future Perspectives for Precision Medicine  
7.1. Clinical Management Using Guideline-Based Indicators (GBIs) 
Diagnosis, prognosis and implications for treatment should be discussed in 
multidisciplinary boards composed by hemato-oncologists, hematopathologists, 
radiologist, human geneticists, molecular biologists, clinical pharmacologist, 
infectiologists, psycho-oncologist, nutritionists and nurses. Moreover, collection of 
relevant clinical data, outcomes and consensus indicators should be supported by 
electronic patient charts and may be integrated in clinical quality development cycles 
[164] (Figure 5). In collaboration with international experts, our study group has 
developed a first set of 29 relevant guideline-based indicators (GBI) as measurable 
elements for quality of care for the domains of diagnosis (n = 14), treatment (n = 8) and 
provider/infrastructural characteristics (n = 7) [46] (Table 9). These GBIs allow the 
structured and systematic assessment of quality of care in adult MDS patients in different 
health care environments using real-world data and will eventually help to identify 
shortcomings for corrective measures. 
 
Figure 5. Clinical development cycles. RWD: Real-world data. Currently, clinical development 
follows generally a liner concept, where clinical research terminates in formulation of guideline 
and recommendations. Clinical development cycles are iterative, feedback processes, where 
adherence to guidelines and recommendations and outcomes are continuously assessed using 
measurable process-based indicators for quality of care. 
Table 9. Guideline-based indicators for adult MDS patients. 
Domain 1 
Diagnosis  
(n = 14) 
Domain 2 
Therapy  




 (n = 7) 
Diagnostic work-up: 
- Cytogenetic analysis 
- BM 
cytology/histology 
- PB assessment 
- WHO 2016 
classification  
Supportive care: 
- Transfusions of RBCs  









- Safe handling of 
cytotoxic drugs 










- TP53 in MDS del(5q) 
Risk stratification: 
- Disease-based risk 
stratification 
- (IPSS/IPSS-R) 
- Patient-based risk 
stratification 





- (IWG criteria 
including LFS, OS) 
- Patient-reported 
outcomes (PROs) 
- Lenalidomide in MDS 
del(5q) 
Higher-risk (unfit patients): 
- Hypomethylating 
agents (HMAs) 
Higher-risk (fit patients): 
- Induction before allo-
HCT  
- (blasts ≥10%) 
- Up-front allo-HCT 
(blasts 5–10%) 






- Teaching and 
continuing 
education 
- Emergency services 
Cooperation: 
- Access to clinical 
trials 
 
Allo-HCT: allogeneic hematopoietic stem cell transplantation; BM: bone marrow; EPO: 
erythropoietin; ESA: erythropoietin stimulating agents; HCT-CI: hematopoietic cell 
transplantation-specific comorbidity index; IPSS/IPSS-R: international prognostic scoring system 
and revised IPSS; IWG: international working group; LFS: leukemia free survival; OS: overall 
survival; MDS-CI: MDS-specific comorbidity index; NGS: next generation sequencing; PB: 
peripheral blood; PROs: patient-reported outcomes; RBCs: red blood cell concentrates; TC: 
thrombocyte concentrates. 
7.2. Diagnosis and Risk-Assessment 
New imaging methods based on digital evaluation of PB smears and BM 
cytomorphology/histopathology slides are increasingly used [165–167]. Several study 
groups aim to develop algorithms for screening, diagnosis, and discrimination from other 
conditions. Follow-up criteria for MDS patients should be better standardized, including 
response criteria, assessment of toxicity, functionality and PROs. MRD detection with 
NGS will be increasingly relevant and may be complemented by single-cell approaches 
for the discrimination of clonal and normal hematopoiesis, the latter of which may be 
relevant for prediction of hematopoietic recovery. With the increased armamentarium of 
therapies, amendable targets such as TP53, IDH1/IDH2, and FLT3-ITD/-TKD should be 
evaluated in the case of suspected progression, even if these markers were absent at 
presentation. 
7.3. Patient Selection for Targeted Therapies 
Appropriate patient selection will be critical for implementation of precision 
medicine in the near future. The fast and reliable generation, interpretation and 
integration of high-dimensional data will require the implementation of novel structures 
and technologies coupled to artificial intelligence to support clinical decision-making. 
Diagnostic procedures and risk-stratification of MDS patients require integration of the 
most relevant clinical data coupled with morphologic, cytogenetic, molecular genetic as 
well as omics-approaches, potentially at single cell resolution. As an example, recent 
studies based on machine learning algorithms suggested combinations of distinct somatic 
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gene mutations or changes in PB values to predict resistance to HMAs [168]. Thus, 
integrative molecular diagnostics coupled to machine learning approaches may become 
increasingly important for MDS diagnostics and targeted therapy in the near future [169]. 
7.4. Understanding Clonal Heterogeneity at Single Cell Resolution 
The introduction of NGS has facilitated the comprehensive detection of the 
mutational landscape in MDS. This has also contributed to highlight the complex clonal 
architecture, explaining the failure of current targeted therapies in achieving clinical cure. 
Therefore, investigations at single-cell resolution may allow delineating the specific 
dependencies and vulnerabilities of the mutant and normal stem cells in order to 
understand individual trajectories of clonal evolution, disease progression or 
hematopoietic recovery. These approaches could allow the design of more effective 
differentiation therapies by resolving ineffective hematopoiesis or even targeting minor 
clones in order to prevent relapse and progression. Prospective national and international 
registries with associated biobanks should be established to enable comprehensive 
translational research with real-world data combined to biomarker analyses in large MDS 
cohorts, as envisaged by our Swiss MDS study group. 
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Abbreviations 
ACMG American College of Medical Genetics 
Allo-HCT Allogeneic hematopoietic stem cell transplantation 
ARCH Age-related clonal hematopoiesis 
ATG Antithymocyte globulin 
AML  Acute myeloid leukemia 
BM Bone marrow 
CCUS Clonal cytopenia of undetermined significance 
CGH Comparative Genomic Hybridization 
CHIP Clonal hematopoiesis of indeterminate potential 
CsA Cyclosporine A 
EMA Erythroid Maturation Agents 
EPO Erythropoietin 
ESA  Erythropoietin Stimulating Agents 
FISH Fluorescent in situ hybridization 
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GBIs Guideline-based indicators 
G-CSF Granulocyte Colony-Stimulating Factor 
G/Rs  Guidelines and recommendations 
HCT-CI  Hematopoietic Cell Transplantation Comorbidity Index 
HI  Hematological improvement 
HMA  Hypomethylating agents 
HSPC Hematopoietic stem and progenitor cells 
HU Hydroxyurea 
ICI Immune checkpoint inhibitor 
ICUS Idiopathic cytopenia of undetermined significance 
IDUS Idiopathic dysplasia of undetermined significance 
IP Immunophenotyping 
IPSS International Prognostic Scoring System  
IPSS-R Revised International Prognostic Scoring System 
IST  Immunosuppressive treatment 
LD-AraC Low-dose cytarabine 
LEN  Lenalidomid 
LUSPA Luspatercept 
MDS  Myelodysplastic syndromes 
MRD Measurable residual disease 
NGS Next generation sequencing 
OS Overall survival 
PB Peripheral blood 
RBC Red blood cell concentrates 
sAML Secondary AML 
SLADMs Somatic leukemia-associated driver mutations  
TC Thrombocyte concentrates 
TLR Toll-like receptor 
TPO-RA Thrombopoietin receptor agonists  
QoL  Quality of life 
VAF Variant allele frequency 
WHO World Health Organization 
WPSS WHO Prognostic Scoring System 
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